期刊文献+

不同剂量新活素治疗充血性心衰疗效和安全性观察 被引量:12

The efficacy and safety of Recombinant Human Brain Natriuretic Peptide in the treatment of congestive heart failure
下载PDF
导出
摘要 目的评价不同剂量新活素治疗充血性心力衰竭(CHF)的疗效及其不良反应。方法 A组30例,给予新活素0.1μg/kg的负荷量静脉注射,随后予0.01μg/(kg·min)持续静脉泵入24 h;B组30例,给予新活素0.1μg/kg的负荷量静脉注射,随后予0.015μg/(kg·min)持续静脉泵入24 h。观察两组用药前后生命体征、呼吸困难程度、体循环淤血及N-末端脑钠肽前体(N-terminal proBNP,NT-proBNP)的变化;1个月时6分钟步行距离和超声心动图评估左心室舒缩末期各径线、左心房径及EF。结果两组比较,在改善呼吸困难和体循环淤血程度等临床症状方面差异有统计学意义(P<0.05);两组患者NT-proBNP水平均较前下降(P<0.05),但两组之间变化差异无统计学意义(P>0.05);1个月时6 min步行距离差异有统计学意义(P<0.05),LVEDD、LVEF差异无统计学意义(P>0.05);低血压、肾功能损害和电解质紊乱的发生率两组之间差异无统计学意义(P>0.05)。结论新活素治疗CHF疗效显著,0.1μg/kg的负荷量静脉注射,随后予0.015μg/(kg·min)持续静脉泵入24 h的疗效更好。 Objective To evaluate the efficacy and safety of Recombinant Human Brain Natriuretic Peptide (RHBNP) in treating CHF at different doses. Methods 60 patients suffered from CHF were enrolled in this study. Patients in group A (n =30) were treated with RHBNP at the dose of 0. 1μg/kg through intravenous injection and followed by the dose of 0.01μg/ (kg * min-1) for 24 hours through intravenous infusion. Patients in group B ( n = 30) were treated with RHBNP at the dose of 0.1 μg/kg through intravenous injection and followed by the dose of 0. 015 μg/ (kg * min-1) for 24 hours through intravenous infusion. Blood pressure, heart rate, the degree of dyspnea, symptoms and NT-pro BNP wero evaluated. Evaluate the radial line, LVEDD and LVEF according to the walking distance in 6min and ultrasonic heartbeat diagram. Results Improvements of dyspnea grade and symptom in group B were better than those of group A ( P 〈 0. 05 ). NT-proBNP levels of both groups decreased compared to the concentration^before treatment ( P 〈 0.05 ) , and the differences between the two groups present no statistically significant ( P 〉 0.05 ). Walk distance in 6rain of the two groups were different from each other (P 〈 0. 05 ). The changes of cardiac function, hypotension and impaired renal function between the two groups had no statistically differences after treatments (P 〉 O. 05 ). Conclusions RHBNP was effective for the treatment of CHR, and will got better efficacy at the dose of 0.1μg/kg through intravenous injection and followed by the dose of 0.01μg/ ( kg * min -1) for 24 hours through intravenous infusion.
出处 《齐齐哈尔医学院学报》 2013年第24期3650-3652,共3页 Journal of Qiqihar Medical University
关键词 心力衰竭 新活素 NT-PROBNP Congestive heart failure Recombinant Human Brain Natriuretic Peptide N-terminal pro-brain natriuretic peptide
  • 相关文献

参考文献7

  • 1孙振国,王鑫,胡志成,李翠,薛浩.急性冠脉综合征中不同程度冠脉病变患者血浆N末端脑钠肽原检测及其意义[J].中国分子心脏病学杂志,2009,9(6):363-365. 被引量:8
  • 2蒋涛,李德才,刘思泰,唐焕君,李健,凌云.2038例慢性心力衰竭住院患者药物治疗动态分析[J].中国现代医学杂志,2007,17(1):76-79. 被引量:20
  • 3Yoshimura M,Yasue H,Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure[J].{H}Canadian Journal of Physiology and Pharmacology,2001,(08):730-735.
  • 4Gordon W,Moe,Jonathan Howlett,James L. Response to Letter Regarding Article,"N-Terminal Pro-B-Type Natriuretic Peptide Testing Imp roves the Management of PatientsWith Suspected Acute Heart Failure:Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE2CHF Study"[J].JCirculation,2008,(01):6.
  • 5Yeo TK,Senger DR,Dvorak HF. Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability fafactor (vascular endothelial growth factor)[J].{H}Journal of Biochemical and Biophysical Research Communications,1991,(03):1568-1575.
  • 6Yancy CW,Saltzberg M,Berkowitz RL. For the FUSION Investigators.Management of patients with congestive heart failure after hospitalization:results from the Follow Up Serial Infusions of Nesiritide(FUSION)trial[J].{H}Journal of Cardiac failure,2003,(5 Suppl):S232-S238.
  • 7Jonathan SB,Hal AS,Keith DA. Risk of worsening renal function with nesiritide in patients with acute decompensated heart failure[J].J Circulation,2005,(12):1489-1491.

二级参考文献20

  • 1张灼辉,谭健强.倍他乐克治疗充血性心力衰竭临床分析[J].中国现代医学杂志,2004,14(17):134-135. 被引量:12
  • 2吕爱莲,张宪南.卡维地洛对慢性心力衰竭患者心功能的影响[J].中国现代医学杂志,2004,14(23):146-147. 被引量:2
  • 3陈忠,马根山,冯毅,罗丹,严金川,沈成兴,戴启明,丁建东.不同类型冠心病病人血浆脑钠肽检测及其意义[J].中国急救医学,2005,25(4):253-254. 被引量:14
  • 4张京梅,李志忠,高玉龙,王苏,刘彤,陶英,卢辛,宋艳东,孙涛,陈玄祖.冠心病患者血浆脑钠肽N末端前体浓度的变化及临床意义[J].北京医学,2007,29(3):129-131. 被引量:15
  • 5Apple, F. S, Standardization of cardiac markers. Scand J Clin Lab Invest Suppl, 2005, 240 : 107-111.
  • 6The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008, 29 ( 19 ) : 2388 -2442.
  • 7Taal BG, M Smits. Developments in diagnosis and treatmeat of metasstatic midgut carcinoid tumors. A review. Minerva Gastroenterol Dietol, 2005,51 (4) : 335-344.
  • 8Ndrepepa G, Braun S, Mehilli J, et al. Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease. Cardiology, 2008, 109 (4) : 249-257.
  • 9Cameron SJ, Sokoll LJ, Laterza OF, et al. A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes. Clin Acta, 2007, 376(1-2) : 168-173.
  • 10Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic pe ptide an d long-term mortality in acute coronary syndromes. Circulation, 2002, 106: 2913-2918.

共引文献26

同被引文献93

引证文献12

二级引证文献114

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部